Search Results - "Renfro, A"

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer by Grothey, Axel, Sobrero, Alberto F, Shields, Anthony F, Yoshino, Takayuki, Paul, James, Taieb, Julien, Souglakos, John, Shi, Qian, Kerr, Rachel, Labianca, Roberto, Meyerhardt, Jeffrey A, Vernerey, Dewi, Yamanaka, Takeharu, Boukovinas, Ioannis, Meyers, Jeffrey P, Renfro, Lindsay A, Niedzwiecki, Donna, Watanabe, Toshiaki, Torri, Valter, Saunders, Mark, Sargent, Daniel J, Andre, Thierry, Iveson, Timothy

“…This analysis involving patients with stage III colon cancer pooled the findings of six clinical trials regarding the effect of adjuvant-therapy duration on…”
Get full text

Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples by Renfro, L.A., Sargent, D.J.

“…In recent years, cancers once viewed as relatively homogeneous in terms of organ location and treatment strategy are now better understood to be increasingly…”
Get full text

Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial by Garcia-Aguilar, Julio, Prof, Renfro, Lindsay A, PhD, Chow, Oliver S, MD, Shi, Qian, PhD, Carrero, Xiomara W, BBA, Lynn, Patricio B, MD, Thomas, Charles R, Prof, Chan, Emily, MD, Cataldo, Peter A, Prof, Marcet, Jorge E, Prof, Medich, David S, MD, Johnson, Craig S, MD, Oommen, Samuel C, MD, Wolff, Bruce G, Prof, Pigazzi, Alessio, MD, McNevin, Shane M, MD, Pons, Roger K, MD, Bleday, Ronald, Prof

“…Summary Background Local excision is an organ-preserving treatment alternative to transabdominal resection for patients with stage I rectal cancer. However,…”
Get full text

Investigating cellular and molecular mechanisms of neurogenesis in Capitella teleta sheds light on the ancestor of Annelida by Sur, A, Renfro, A, Bergmann, P J, Meyer, N P

“…Diverse architectures of nervous systems (NSs) such as a plexus in cnidarians or a more centralized nervous system (CNS) in insects and vertebrates are present…”
Get full text

Bayesian Response Adaptive Randomization for Randomized Clinical Trials With Continuous Outcomes: The Role of Covariate Adjustment by Aslanyan, Vahan, Pickering, Trevor, Nuño, Michelle, Renfro, Lindsay A, Pa, Judy, Mack, Wendy J

“…Study designs incorporate interim analyses to allow for modifications to the trial design. These analyses may aid decisions regarding sample size, futility,…”
Get full text

ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer by RENFRO, Lindsay A, GROTHEY, Axel, YOTHERS, Greg, SARGENT, Daniel J, YUAN XUE, SALTZ, Leonard B, ANDRE, Thierry, TWELVES, Chris, LABIANCA, Roberto, ALLEGRA, Carmen J, ALBERTS, Steven R, LOPRINZI, Charles L

“…Current prognostic tools in colon cancer use relatively few patient characteristics. We constructed and validated clinical calculators for overall survival…”
Get full text

Surrogate End Points in Soft Tissue Sarcoma: Methodologic Challenges by Renfro, Lindsay A, Shi, Qian, Sargent, Daniel J

Get full text

Prospective Multicenter Study of the Impact of Oncotype DX Colon Cancer Assay Results on Treatment Recommendations in Stage II Colon Cancer Patients by Srivastava, Geetika, Renfro, Lindsay A., Behrens, Robert J., Lopatin, Margarita, Chao, Calvin, Soori, Gamini S., Dakhil, Shaker R., Mowat, Rex B., Kuebler, J. Philip, Kim, George, Mazurczak, Miroslaw, Lee, Mark, Alberts, Steven R.

“…Purpose. The Oncotype DX colon cancer assay is a clinically validated predictor of recurrence risk in stage II colon cancer patients. This prospective study…”
Get full text

Definitions and statistical properties of master protocols for personalized medicine in oncology by Renfro, Lindsay A., Mandrekar, Sumithra J.

“…Within the field of cancer research, discovery of biomarkers and genetic mutations that are potentially predictive of treatment benefit is motivating a…”
Get full text

Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer by Foster, Nathan R, Renfro, Lindsay A, Schild, Steven E, Redman, Mary W, Wang, Xiaofei F, Dahlberg, Suzanne E, Ding, Keyue, Bradbury, Penelope A, Ramalingam, Suresh S, Gandara, David R, Shibata, Taro, Saijo, Nagahiro, Vokes, Everett E, Adjei, Alex A, Mandrekar, Sumithra J

“…We previously reported that progression-free survival (PFS) may be a candidate surrogate end point for overall survival (OS) in first-line extensive-stage…”
Get more information

Center-within-trial versus trial-level evaluation of surrogate endpoints by Renfro, Lindsay A., Shi, Qian, Xue, Yuan, Li, Junlong, Shang, Hongwei, Sargent, Daniel J.

“…Evaluation of candidate surrogate endpoints using individual patient data from multiple clinical trials is considered the gold standard approach to validate…”
Get full text

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project by Sjoquist, Katrin M, Renfro, Lindsay A, Simes, R John, Tebbutt, Niall C, Clarke, Stephen, Seymour, Matthew T, Adams, Richard, Maughan, Timothy S, Saltz, Leonard, Goldberg, Richard M, Schmoll, Hans-Joachim, Van Cutsem, Eric, Douillard, Jean-Yves, Hoff, Paulo M, Hecht, Joel Randolph, Tournigand, Christophe, Punt, Cornelis J A, Koopman, Miriam, Hurwitz, Herbert, Heinemann, Volker, Falcone, Alfredo, Porschen, Rainer, Fuchs, Charles, Diaz-Rubio, Eduardo, Aranda, Enrique, Bokemeyer, Carsten, Souglakos, Ioannis, Kabbinavar, Fairooz F, Chibaudel, Benoist, Meyers, Jeffrey P, Sargent, Daniel J, de Gramont, Aimery, Zalcberg, John R

“…Abstract Background Estimating prognosis on the basis of clinicopathologic factors can inform clinical practice and improve risk stratification for clinical…”
Get full text

Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials by Renfro, Lindsay A., Shi, Qian, Sargent, Daniel J., Carlin, Bradley P.

“…A two‐stage model for evaluating both trial‐level and patient‐level surrogacy of correlated time‐to‐event endpoints has been introduced, using patient‐level…”
Get full text

Improving ecosystem health in highly altered river basins: a generalized framework and its application to the Mississippi-Atchafalaya River Basin by McLellan, Eileen L, Suttles, Kelly M, Bouska, Kristen L, Ellis, Jamelle H, Flotemersch, Joseph E, Goff, Madison, Golden, Heather E, Hill, Ryan A, Hohman, Tara R, Keerthi, Shamitha, Keim, Richard F, Kleiss, Barbara A, Lark, Tyler J, Piazza, Bryan P, Renfro, Alisha A, Robertson, Dale M, Schilling, Keith E, Schmidt, Travis S, Waite, Ian R

“…Continued large-scale public investment in declining ecosystems depends on demonstrations of "success". While the public conception of "success" often focuses…”
Get full text

Navigating the Fine Line between the Bad and Worse. The issue is not the number, and the message is not “all or nothing” by Calcaterra, Domenico, MD, Renfro, Leslie A., MD, Shander, Aryeh, MD

Get full text

Prospective Evaluation of a 12-gene assay on patient treatment decisions and physician confidence in mismatch repair proficient stage IIA colon cancer by Renfro, Lindsay A, Zhang, Nan, Lopatin, Margarita, Chao, Calvin, Alberts, Steven R

“…Abstract Background The Onco type DX Colon Cancer Assay is a validated predictor of recurrence risk in patients with resected stage II colon cancer. We…”
Get full text

Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer by Alberts, Steven R., Yu, Tiffany M., Behrens, Robert J., Renfro, Lindsay A., Srivastava, Geetika, Soori, Gamini S., Dakhil, Shaker R., Mowat, Rex B., Kuebler, John P., Kim, George P., Mazurczak, Miroslaw A., Hornberger, John

“…Background Prior economic analysis that compared the 12-gene assay to published patterns of care predicted the assay would improve outcomes while lowering…”
Get full text

Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population by Renfro, L.A., Grothey, A., Kerr, D., Haller, D.G., André, T., Van Cutsem, E., Saltz, L., Labianca, R., Loprinzi, C.L., Alberts, S.R., Schmoll, H., Twelves, C., Yothers, G., Sargent, D.J., Sargent, D.J., Green, E., Grothey, A., Alberts, S.R., Shi, Q., Renfro, L.A., Yothers, G., O'Connell, M.J., Wolmark, N., de Gramont, A., Gray, R., Kerr, D., Haller, D.G., Guthrie, K., Buyse, M., Labianca, R., Seitz, J.F., O'Callaghan, C.J., Francini, G., Catalano, P.J., Blanke, C.D., Andre, T., Goldberg, R.M., Benson, A., Twelves, C., Sirzen, F., Cisar, L., Van Cutsem, E., Saltz, L.

“…It is unclear how long-term survival of treated early-stage colon cancer (CC) patients differs the general population. We compared survival of 32 745 CC trial…”
Get full text

Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the power of pooled individual patient data from multiple clinical trials by Renfro, Lindsay A, Sargent, Daniel J

“…The Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group was formed 15 years ago to address scientific questions in early stage colon cancer that…”
Get full text

Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer by Sanoff, Hanna K, Renfro, Lindsay A, Poonnen, Pradeep, Ambadwar, Pratibha, Sargent, Daniel J, Goldberg, Richard M, McLeod, Howard

“…Colorectal cancer (CRC) risk is partly conferred by common, low-penetrance single nucleotide polymorphisms (SNPs). We hypothesized that these SNPs are…”
Get full text